NCT03502733 2026-03-19
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
15 trialsNCT06385483 2026-03-19
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06400238 2026-03-19
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT04301076 2026-03-18
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05490771 2026-03-18
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06308822 2026-03-18
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390826 2026-03-17
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390839 2026-03-17
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05371132 2026-01-28
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
City of Hope Medical Center
Phase 1 Recruiting
NCT04320888 2025-12-04
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05011045 2025-11-10
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
Recruiting
NCT06390852 2025-11-04
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06390865 2025-11-04
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06385496 2025-10-31
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
National Cancer Institute (NCI)
Phase 2 Active not recruiting